Morepen Laboratories share news, announcements and annual reports
NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap
Morepen Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 1993 on BSE, Nov 1999 on NSE
Last close ₹113.35down ₹5.96 (5.00%)BSE ₹113.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹119.31.
30 Oct: open ₹113.35, high ₹122.23, low ₹113.35
52-week range of traded prices to 30 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,211 Cr1,108th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 32.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 88,57,838
Morepen Laboratories share news and announcements
608 announcements, routine notices left out, newest first. Page 9 of 13.
Aug 2018
13 Aug · Results
Jul 2018
23 Jul · Board meeting
Jun 2018
25 Jun · Analysts
May 2018
16 May · Analysts
16 May · Results
16 May · Board meeting
Apr 2018
Mar 2018
Feb 2018
2 Feb · Analysts
Jan 2018
22 Jan · Analysts
22 Jan · Results
Dec 2017
Nov 2017
10 Nov · Results
10 Nov · Board meeting
9 Nov · News Verification
Exchange has sought clarification from Morepen Laboratories Limited with respect to recent news item captioned "Morepen to partner Belgian firm for probiotic products". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Sep 2017
22 Sep · Meeting
11 Sep · Results
Aug 2017
Apr 2017
29 Apr · Results
Feb 2017
8 Feb · Results
Jan 2017
Nov 2016
9 Nov · Legal
Exchange has sought clarification from Morepen Laboratories Limited with respect to announcement dated 09-Nov-2016, regarding the outcome of meeting of the Board of Directors of the Company held on November 09, 2016.On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.9 Nov · Results
Oct 2016
Sep 2016